These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 35306156)
1. Tumor budding is an independent prognostic factor in stage III colon cancer patients: a post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR). Basile D; Broudin C; Emile JF; Falcoz A; Pagès F; Mineur L; Bennouna J; Louvet C; Artru P; Fratte S; Ghiringhelli F; André T; Derangère V; Vernerey D; Taieb J; Svrcek M; Ann Oncol; 2022 Jun; 33(6):628-637. PubMed ID: 35306156 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of Tumor Budding in Predicting Survival for Gastric Carcinoma Patients in Vietnam. Dao TV; Nguyen CV; Nguyen QT; Vu HTN; Phung HT; Bui OT; Nguyen DK; Luong BV; Tran TV Cancer Control; 2020; 27(1):1073274820968883. PubMed ID: 33136444 [TBL] [Abstract][Full Text] [Related]
3. Tumour budding in pancreatic cancer revisited: validation of the ITBCC scoring system. Karamitopoulou E; Wartenberg M; Zlobec I; Cibin S; Worni M; Gloor B; Lugli A Histopathology; 2018 Jul; 73(1):137-146. PubMed ID: 29495092 [TBL] [Abstract][Full Text] [Related]
4. Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study. Pagès F; André T; Taieb J; Vernerey D; Henriques J; Borg C; Marliot F; Ben Jannet R; Louvet C; Mineur L; Bennouna J; Desrame J; Faroux R; Kirilovsky A; Duval A; Laurent-Puig P; Svrcek M; Hermitte F; Catteau A; Galon J; Emile JF Ann Oncol; 2020 Jul; 31(7):921-929. PubMed ID: 32294529 [TBL] [Abstract][Full Text] [Related]
5. Is there no need to discuss adjuvant chemotherapy in stage II colon cancer patients with high tumor budding and lymphovascular invasion? Zenger S; Gurbuz B; Can U; Erginoz E; Ozata IH; Yilmaz SP; Taskin OC; Peker O; Adsay V; Balik E; Bugra D Langenbecks Arch Surg; 2023 Mar; 408(1):127. PubMed ID: 36973561 [TBL] [Abstract][Full Text] [Related]
6. Prognostic and predictive values of tumour budding in stage IV colorectal cancer. Nagata K; Shinto E; Yamadera M; Shiraishi T; Kajiwara Y; Okamoto K; Mochizuki S; Hase K; Kishi Y; Ueno H BJS Open; 2020 Aug; 4(4):693-703. PubMed ID: 32472647 [TBL] [Abstract][Full Text] [Related]
7. Prognostic value of tumour budding in stomach cancers. Kucuk S Int J Clin Pract; 2021 Dec; 75(12):e14922. PubMed ID: 34580963 [TBL] [Abstract][Full Text] [Related]
8. Prognostic Value of Tumor Deposits for Disease-Free Survival in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the IDEA France Phase III Trial (PRODIGE-GERCOR). Delattre JF; Cohen R; Henriques J; Falcoz A; Emile JF; Fratte S; Chibaudel B; Dauba J; Dupuis O; Bécouarn Y; Bibeau F; Taieb J; Louvet C; Vernerey D; André T; Svrcek M J Clin Oncol; 2020 May; 38(15):1702-1710. PubMed ID: 32167864 [TBL] [Abstract][Full Text] [Related]
9. Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Taieb J; Taly V; Henriques J; Bourreau C; Mineur L; Bennouna J; Desrame J; Louvet C; Lepere C; Mabro M; Egreteau J; Bouche O; Mulot C; Hormigos K; Chaba K; Mazard T; de Gramont A; Vernerey D; André T; Laurent-Puig P Clin Cancer Res; 2021 Oct; 27(20):5638-5646. PubMed ID: 34083233 [TBL] [Abstract][Full Text] [Related]
10. Validation of the International Tumor Budding Consensus Conference 2016 recommendations on tumor budding in stage I-IV colorectal cancer. Dawson H; Galuppini F; Träger P; Berger MD; Studer P; Brügger L; Zlobec I; Inderbitzin D; Lugli A Hum Pathol; 2019 Mar; 85():145-151. PubMed ID: 30428391 [TBL] [Abstract][Full Text] [Related]
11. Differential effect of tumor budding on the benefit of adjuvant chemotherapy in stage II colorectal cancer: a retrospective observational study. Ran X; Chen Y; Liu C; Xiao H; Su X; Chen Z; Du J; He J; Zhong P; Li M; Dai N; Chen C J Gastrointest Oncol; 2024 Aug; 15(4):1545-1555. PubMed ID: 39279933 [TBL] [Abstract][Full Text] [Related]
12. Prospective Multicenter Study on the Prognostic and Predictive Impact of Tumor Budding in Stage II Colon Cancer: Results From the SACURA Trial. Ueno H; Ishiguro M; Nakatani E; Ishikawa T; Uetake H; Matsuda C; Nakamoto Y; Kotake M; Kurachi K; Egawa T; Yasumasa K; Murata K; Ikawa O; Shinji S; Murotani K; Matsui S; Teramukai S; Tomita N; Sugihara K; J Clin Oncol; 2019 Aug; 37(22):1886-1894. PubMed ID: 31180819 [TBL] [Abstract][Full Text] [Related]
13. Tumor budding and poorly-differentiated cluster in prognostication in Stage II colon cancer. Lee VWK; Chan KF Pathol Res Pract; 2018 Mar; 214(3):402-407. PubMed ID: 29487008 [TBL] [Abstract][Full Text] [Related]
14. Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer. Mlecnik B; Bifulco C; Bindea G; Marliot F; Lugli A; Lee JJ; Zlobec I; Rau TT; Berger MD; Nagtegaal ID; Vink-Börger E; Hartmann A; Geppert C; Kolwelter J; Merkel S; Grützmann R; Van den Eynde M; Jouret-Mourin A; Kartheuser A; Léonard D; Remue C; Wang JY; Bavi P; Roehrl MHA; Ohashi PS; Nguyen LT; Han S; MacGregor HL; Hafezi-Bakhtiari S; Wouters BG; Masucci GV; Andersson EK; Zavadova E; Vocka M; Spacek J; Petruzelka L; Konopasek B; Dundr P; Skalova H; Nemejcova K; Botti G; Tatangelo F; Delrio P; Ciliberto G; Maio M; Laghi L; Grizzi F; Fredriksen T; Buttard B; Lafontaine L; Bruni D; Lanzi A; El Sissy C; Haicheur N; Kirilovsky A; Berger A; Lagorce C; Paustian C; Ballesteros-Merino C; Dijkstra J; van de Water C; van Lent-van Vliet S; Knijn N; Muşină AM; Scripcariu DV; Popivanova B; Xu M; Fujita T; Hazama S; Suzuki N; Nagano H; Okuno K; Torigoe T; Sato N; Furuhata T; Takemasa I; Itoh K; Patel PS; Vora HH; Shah B; Patel JB; Rajvik KN; Pandya SJ; Shukla SN; Wang Y; Zhang G; Kawakami Y; Marincola FM; Ascierto PA; Fox BA; Pagès F; Galon J J Clin Oncol; 2020 Nov; 38(31):3638-3651. PubMed ID: 32897827 [TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of tumour budding assessed in gastric carcinoma according to the criteria of the International Tumour Budding Consensus Conference. Ulase D; Heckl S; Behrens HM; Krüger S; Röcken C Histopathology; 2020 Feb; 76(3):433-446. PubMed ID: 31538348 [TBL] [Abstract][Full Text] [Related]
16. Association of tumor budding with clinicopathological features and prognostic value in stage III-IV colorectal cancer. Luo YH; Yan ZC; Liu JY; Li XY; Yang M; Fan J; Huang B; Ma CG; Chang XN; Nie X World J Gastroenterol; 2024 Jan; 30(2):158-169. PubMed ID: 38312121 [TBL] [Abstract][Full Text] [Related]
18. Refining the ITBCC tumor budding scoring system with a "zero-budding" category in colorectal cancer. Zlobec I; Bächli M; Galuppini F; Berger MD; Dawson HE; Nagtegaal ID; Lugli A Virchows Arch; 2021 Dec; 479(6):1085-1090. PubMed ID: 33843013 [TBL] [Abstract][Full Text] [Related]
19. Tumour budding in preoperative biopsy specimens is a useful prognostic index for identifying high-risk patients in early-stage (pN0) colon cancer. Zengin M; Çifci A Turk J Med Sci; 2020 Apr; 50(2):375-385. PubMed ID: 32011836 [TBL] [Abstract][Full Text] [Related]
20. No time to die: the consensus immunoscore for predicting survival and response to chemotherapy of locally advanced colon cancer patients in a multicenter international study. Ascierto PA; Marincola FM; Fox BA; Galon J Oncoimmunology; 2020 Oct; 9(1):1826132. PubMed ID: 33194317 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]